title: Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder.
abstract: Genetic polymorphism of the serotonin 5-HT(2A) receptor seems to be associated with therapeutic response to selective serotonin reuptake inhibitors (SSRIs). The present study investigated whether a novel -1438G/A polymorphism in the promoter region of the 5-HT(2A )receptor gene is associated with therapeutic response to fluvoxamine (an SSRI) in 66 Japanese patients with major depressive disorder. Fluvoxamine (50 to 200 mg) was administered twice daily for 6 weeks. Fifty-four patients completed this study. The genotype distribution and the allele frequencies showed no significant difference between responders and non-responders. The time-course of the Montgomery-Asberg Depression Rating Scale scores showed no significant difference among -1438G/G, -1438G/A, and -1438A/A genotype groups. The results demonstrated that the -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene was unlikely to have a major role in therapeutic response to fluvoxamine in Japanese patients with major depressive disorder.
authors.affiliation: Department of Psychiatry, Akita University School of Medicine, Akita, Japan. ICD45422@nifty.com
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Sato
authors.forename: Keizo
authors.initials: K
authors.lastname: Yoshida
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Takahashi
authors.forename: Kenichi
authors.initials: K
authors.lastname: Ito
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Kamata
authors.forename: Hisashi
authors.initials: H
authors.lastname: Higuchi
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Shimizu
authors.forename: Kunihiko
authors.initials: K
authors.lastname: Itoh
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Inoue
authors.forename: Takehiko
authors.initials: T
authors.lastname: Tezuka
authors.forename: Toshio
authors.initials: T
authors.lastname: Suzuki
authors.forename: Taashi
authors.initials: T
authors.lastname: Ohkubo
authors.forename: Kazunobu
authors.initials: K
authors.lastname: Sugawara
authors.forename: Koichi
authors.initials: K
authors.lastname: Otani
mesh_terms: D000328:Adult; D000368:Aged; D016009:Chi-Square Distribution; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000235:genetics; D004305:Dose-Response Relationship, Drug; D005260:Female; D016666:Fluvoxamine / Q000097:blood / Q000627:therapeutic use*; D005787:Gene Frequency; D005838:Genotype; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D011401:Promoter Regions, Genetic / Q000235:genetics*; D011569:Psychiatric Status Rating Scales; D044402:Receptor, Serotonin, 5-HT2A; D011985:Receptors, Serotonin / Q000235:genetics*; D017367:Selective Serotonin Reuptake Inhibitors / Q000097:blood / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D016666:Fluvoxamine; D044402:Receptor, Serotonin, 5-HT2A; D011985:Receptors, Serotonin; D017367:Selective Serotonin Reuptake Inhibitors